The U.S. Food and Drug Administration (FDA) revised the Boxed Warning on the label for Metformin Hydrochloride, effective 2026-05-19. This revision updates information regarding the risk of lactic acidosis, a rare but serious metabolic complication associated with metformin use. Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias.
Background
A Boxed Warning, also known as a black box warning, is the strongest warning that the FDA requires for prescription drugs. It is designed to call attention to serious or life-threatening risks. For Metformin Hydrochloride, this revised warning specifically addresses lactic acidosis, a rare but severe metabolic complication. The warning details that postmarketing cases of metformin-associated lactic acidosis have resulted in serious outcomes including death, hypothermia, hypotension, and resistant bradyarrhythmias. It also notes that the onset of metformin-associated lactic acidosis is often subtle, making early detection and intervention crucial for patient safety.
What this means
The revision of the Boxed Warning for Metformin Hydrochloride provides updated critical safety information for healthcare providers and patients. This update underscores the importance of vigilance for the signs and symptoms of lactic acidosis, especially given its often subtle onset and potentially fatal consequences. Clinicians should review the updated label to ensure they are fully informed about the current recommendations for monitoring patients, identifying risk factors, and managing this serious adverse event associated with Metformin Hydrochloride. Patient advocates and researchers can use this revised warning to inform discussions about drug safety and patient education regarding metformin use.
Source
This information is based on a label revision for Metformin Hydrochloride issued by the FDA, effective 2026-05-19. The details of the revised Boxed Warning are available on dailymed.nlm.nih.gov.